Renalytix appoints Ann Berman to board

Renalytix announced the appointment of Ann Berman to its board on Wednesday, as chair of its audit committee and a member of the nomination committee.

The AIM-traded firm said Berman currently served on the board of directors and as a member of the audit committee of Loews Corporation.

In addition, she is a member of the board of trustees of Beth Israel Deaconess Medical Center, where she is the chair of the compliance and risk committees, and Immuneering Corporation, where she chairs the audit committee.

“We are delighted to have a professional of Ann's capabilities on board as Renalytix enters into a substantial growth phase,” said interim chairman Christopher Mills.

“Her leadership and operational experience will be invaluable to helping us drive shareholder value.”

Before her retirement in 2009, Berman served as chief financial officer of Harvard University, where she was responsible for financial strategy, policy and planning, financial reporting and operations, treasury and risk management, and various audit functions.

As part of her role, she served on the board of Harvard Management Company, the investment management firm for Harvard University's endowment.

Before joining Harvard, Berman was a partner with Richard A. Eisner & Co, an accounting firm, from 1978 to 1985, having began her career in finance at Price Waterhouse.

She is a certified public accountant who is qualified as a financial expert for audit committee leadership, with extensive experience overseeing audit-related matters, enterprise risk management, internal audit, cybersecurity, and compliance.

Berman earned a B.A. in French language and literature at Cornell University, Phi Beta Kappa, and an M.B.A. with a concentration in accounting from the University of Pennsylvania's Wharton School of Business.

“Renalytix is doing important and exciting work in improving the care and treatment of kidney disease,” said Ann Berman.

“I am very pleased to contribute my expertise to advancing the company and supporting its goals.”

At 1021 BST, shares in Renalytix AI were up 0.91% at 1,105p.